Beijing Hotgen Biotech Co., Ltd.

Shanghai Stock Exchange 688068.SS

Beijing Hotgen Biotech Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 11.30

Beijing Hotgen Biotech Co., Ltd. Price to Sales Ratio (P/S) is 11.30 on January 14, 2025, a 78.94% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Beijing Hotgen Biotech Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 12.75 on January 07, 2025, which is 12.82% above the current Price to Sales Ratio (P/S).
Beijing Hotgen Biotech Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 3.95 on September 18, 2024, which is -65.00% below the current Price to Sales Ratio (P/S).
Beijing Hotgen Biotech Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 5.65.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 688068.SS

Beijing Hotgen Biotech Co., Ltd.

CEO	Mr. Changqing Lin
IPO Date	Sept. 30, 2019
Location	China
Headquarters	Zhongguancun High-end Medical Device Ind
Employees	1,036
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers drug detection, CDC, Up-conversion luminescence technology, colloidal gold, CLIA, sugar capture, microfluidic, and gene detection products for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. The company was founded in 2005 and is based in Beijing, China.

Key trends

Past 5 years